Drug intelligence / Profile preview

DA-9805

Development stage
Phase 2
Lead developer
Dong-A ST
Modality
Small Molecules
Administration
Oral
01

Overview

DA-9805 is a botanical drug candidate developed for the treatment of Parkinson's disease. It is an ethanolic extract mixture derived from three traditional medicinal plants—Moutan cortex (root bark of Paeonia suffruticosa), Angelica dahurica root, and Bupleurum falcatum root—in equal proportions. The formulation has demonstrated neuroprotective effects in preclinical models by alleviating mitochondrial damage, oxidative stress, endoplasmic reticulum (ER) stress, and neuroinflammation. Mechanistically, DA-9805 acts as an antioxidant and modulates mitochondrial proteins; it also normalizes neurotransmitter imbalances in the striatum by restoring dopamine transmission and reducing elevated acetylcholine levels through modulation of choline acetyltransferase expression. These actions contribute to improved motor function and protection against dopaminergic neuronal loss in experimental models of Parkinson’s disease[1][2][3][4][6].

Other names
triple herbal extract DA-9805
02

Targets

CHAT (Choline acetyltransferase)NADH:ubiquinone oxidoreductase subunit familyNF-κB

Beyond the preview

Go deeper on DA-9805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-9805.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call